Literature DB >> 10933802

Decreased lateral aggregation of a variant recombinant fibrinogen provides insight into the polymerization mechanism.

J L Mullin1, O V Gorkun, S T Lord.   

Abstract

We analyzed the polymerization of BbetaA68T fibrinogen, the recombinant counterpart of fibrinogen Naples, a variant known to have decreased thrombin binding. When polymerized with equal thrombin concentrations, BbetaA68T fibrinogen had a longer lag time and lower rate of lateral aggregation, V(max), than normal recombinant fibrinogen, but a similar final turbidity. At thrombin concentrations that equalized the rates of fibrinopeptide A release, BbetaA68T fibrinogen polymerized with a lag time and V(max) similar to normal, but reached a significantly lower final turbidity. Similar results were produced when BbetaA68T was polymerized with Ancrod, which cleaves fibrinopeptide A at the same rate from either fibrinogen, and when BbetaA68T desA monomers were polymerized. The polymerization of desAB fibrin monomers, which circumvents fibrinopeptide release, was the same for both fibrinogens. We confirmed that turbidity was indicative of fiber thickness by scanning electron microscopy of fibrin clots. Here, we present the first experimental evidence of fibrin polymerization with a normal period of protofibril formation and rate of lateral aggregation, but with a significantly decreased extent of lateral aggregation. We conclude that the decreased lateral aggregation seen in BbetaA68T fibrinogen is due to an altered step in the enzymatic phase of its polymerization process. We propose that during normal polymerization a subtle conformational change in the E domain occurs, between the release of FpA and FpB, and that this change modulates the mechanism of lateral aggregation. Without this change, the lateral aggregation of BbetaA68T fibrinogen is impaired such that variant clots have thinner fibers than normal clots.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933802     DOI: 10.1021/bi000045c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Substitution of the human αC region with the analogous chicken domain generates a fibrinogen with severely impaired lateral aggregation: fibrin monomers assemble into protofibrils but protofibrils do not assemble into fibers.

Authors:  Lifang Ping; Lihong Huang; Barbara Cardinali; Aldo Profumo; Oleg V Gorkun; Susan T Lord
Journal:  Biochemistry       Date:  2011-09-27       Impact factor: 3.162

Review 2.  Mechanisms of fibrin polymerization and clinical implications.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Blood       Date:  2013-01-10       Impact factor: 22.113

Review 3.  Fibrin Formation, Structure and Properties.

Authors:  John W Weisel; Rustem I Litvinov
Journal:  Subcell Biochem       Date:  2017

4.  Fibrinogen variant BbetaD432A has normal polymerization but does not bind knob "B".

Authors:  Sheryl R Bowley; Susan T Lord
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

5.  The presence of gamma' chain impairs fibrin polymerization.

Authors:  Kathryn C Gersh; Chandrasekaran Nagaswami; John W Weisel; Susan T Lord
Journal:  Thromb Res       Date:  2009-01-12       Impact factor: 3.944

6.  Impaired protofibril formation in fibrinogen gamma N308K is due to altered D:D and "A:a" interactions.

Authors:  Sheryl R Bowley; Nobuo Okumura; Susan T Lord
Journal:  Biochemistry       Date:  2009-09-15       Impact factor: 3.162

7.  Does topology drive fiber polymerization?

Authors:  Lihong Huang; Joe Ping-Lin Hsiao; Camilla Powierza; Russell M Taylor; Susan T Lord
Journal:  Biochemistry       Date:  2014-12-05       Impact factor: 3.162

8.  Structural and Functional Characterization of Four Novel Fibrinogen Mutations in FGB Causing Congenital Fibrinogen Disorder.

Authors:  Eliška Ceznerová; Jiřina Kaufmanová; Žofie Sovová; Jana Štikarová; Jan Loužil; Roman Kotlín; Jiří Suttnar
Journal:  Int J Mol Sci       Date:  2022-01-10       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.